Interleukin (IL)-23 is a member of the IL-12 family of heterodimeric cytokines, comprised of p19 and p40 subunits, which exhibits immunostimulatory properties similar to IL-12. We have demonstrated previously that adenoviral-mediated, intratumoral delivery of IL-23 (Ad.IL-23) was able to induce systemic antitumor immunity. Here we demonstrate that Ad.IL-23 requires endogenous IL-12 for conferring an antitumor effect after adenoviral-mediated, intratumoral delivery. In contrast, Ad.IL-12 does not require IL-23 for its antitumor effects although endogenous IL-23 appears important for induction of systemic antitumor immunity by IL-12. However, despite the requirement for endogenous IL-12, co-delivery of IL-23 and IL-12 does not provide even an additive local or systemic antitumor effect, regardless of the dose. We further demonstrate that although the use of a single-chain IL-23 (scIL-23) results in higher level of expression and a more pronounced IL-23-mediated antitumor effect, there is still no synergy with IL-12. These results demonstrate that although significant antitumor effects are achieved by intratumoral injection of adenovirus expressing either scIL-23 or IL-12 alone and that IL-23 requires endogenous IL-12 for maximum antitumor benefit, the combined use of these cytokines provides no additive or synergistic effect.
Introduction
Interleukin (IL)-12 is a heterodimeric, proinflammatory cytokine comprised of p40 and p35 subunits. IL-12 enhances proliferation 1 and cytolytic activity 2, 3 of and IFN-g production from activated natural killer and T cells. 2, 4, 5 In response to microbial infection, IL-12 is produced by macrophages, which in turn drives generation of a Th1-type adaptive immune response. Therefore, IL-12 acts as a bridge between both innate and adaptive arms of the immune system. 6 IFN-g is responsible for the majority of the inflammatory activities of IL-12, drives Th1 differentiation and induces IL-12 secretion from dendritic cells (DCs), thereby forming a positive feedback loop for Th1 differentiation. 7 IL-12 activates the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway, with STAT4 being preferentially activated. 8 In accordance with the proinflammatory and immunostimulatory activities of this cytokine, IL-12 possesses potent antitumor effects. Indeed, recombinant IL-12 has been shown to inhibit tumor establishment, cause regression of established tumors and induce tumorspecific immunity. [9] [10] [11] [12] However, systemically delivered IL-12 is associated with severe toxicity. 12 Gene delivery of IL-12 directly into the tumor microenvironment using adenoviral vectors promotes tumor regression and generation of tumor-specific immunity, while alleviating the toxicity associated with systemic delivery. 13 IL-23 is a member of the IL-6/IL-12 family of heterodimeric cytokines and is composed of two subunits: p40, which is shared with IL-12, and p19, which is unique to IL-23.
14 Like IL-12, IL-23 can act on both innate and adaptive arms of immunity. IL-23 stimulates production of IFN-g from natural killer cells. 15 Furthermore, IL-23 stimulates proliferation of and IFN-g production from CD4 þ memory T cells, suggesting an important role in maintenance of Th1 immunity.
14 IL-23 activates the same panel of signaling molecules as IL-12, differing only in that STAT3, as opposed to STAT4, appears to be the most prominent STAT activated. 16 Owing to the structural and functional similarities between IL-12 and IL-23, it is not surprising that IL-23 also acts as a potent anticancer agent in various establishment [17] [18] [19] [20] and therapeutic [21] [22] [23] models of cancer. We previously have shown that treatment of established MCA205 fibrosarcoma tumors with adenovirus expressing IL-23 leads to significant enhancement of survival, tumor rejection and establishment of protective immunity using mechanisms similar to IL-12. 23 IL-12 and IL-23 both activate the JAK/STAT pathway, 8, 16 induce IFN-g production from natural killer and T cells, 2, 4, 5, 14, 15 and utilize common mechanisms of tumor eradication. 23 Furthermore, IL-23 acts on DCs to induce IL-12 production, and the combination of IL-12 and IL-23 causes DCs to secrete greater levels of IFN-g than either cytokine alone. 24 Here we examined whether endogenous IL-12 and IL-23 are required for the antitumor effects of adenovirally delivered IL-12 and IL-23. We further examined whether IL-12 and IL-23 function in an additive or synergistic manner in conferring antitumor effects.
Materials and methods

Adenoviruses
Adenoviruses expressing IL-12 (Ad.IL-12) and IL-23 (Ad.IL-23) have been described previously. 13, 25 Ad.IL-12, Ad.IL-23 and Ad.Psi5 (empty vector) were prepared as follows: Viruses were propagated on HEK-293 cells and purified by cesium chloride banding, followed by dialysis in 3% sucrose solution. Particle titer of purified viruses was determined by spectroscopy using the equation, (OD 260 ) (dilution factor)/9.09 Â 10
À13
, with the virus being diluted 1:50 before measuring OD. The particle titer was used to calculate multiplicity of infection (MOI) in all experiments. Infectious titers were determined using quantitative real-time PCR as previously described 26 and were B100-fold less than particle titers. Viruses were aliquoted and stored at À80 1C until use.
Adenoviruses expressing single-chain (sc) versions of IL-12 and IL-23 were designed as follows: To construct Ad.scIL-12, the IL-12p40 precursor (Met1 to Ser335) was linked to the mature p35 subunit (Arg23 to Ala215) using the previously described 15-amino-acid linker (Gly 4 Ser) 3 . 27 To construct Ad.scIL-23, the IL-12 p40 precursor (Met1 to Ser335) was linked to the mature p19 subunit (Leu20 to Ala196) using (Gly 4 Ser) 3 .
Relative cytokine expression of each adenoviral preparation was analyzed by infecting 4 Â 10 4 MCA205 cells with a 500 MOI of Ad.IL-12 or Ad.IL-23 for 1 h at 37 1C/5% CO 2 in serum-free media. Complete media was added and cells were incubated for 72 h, after which supernatants were harvested. IL-12 and IL-23 contents were analyzed using the mouse IL-12 p70 and mouse IL-23 p19/p40 Ready-Set-Go IL-23 ELISA kits (eBioscience, San Diego, CA), respectively, following manufacturers' instructions.
Biological activity of Ad. 
Animals
Female C57BL/6 and p40-deficient mice on a C57BL/6 background were obtained from The Jackson Laboratory (Bar Harbor, ME). IL-23-(p19) deficient mice have been previously described and were a kind gift of Dr Jay Kolls. 28 Mice were used at 6-7 weeks of age. Animals were maintained under pathogen-free conditions at the Biotechnology Center Animal facility at the University of Pittsburgh. All procedures preformed were approved by the University of Pittsburgh Institutional Animal Care and Use Committee.
Cell Lines MCA205 fibrosarcoma cells were maintained in Roswell Park Memorial Institute medium supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/ streptomycin (Gibco, Carlsbad, CA) and L-glutamine (Gibco). Cells were kept in a humidified chamber at 37 1C/5% CO 2 and passaged every 2-3 days. Psi5 . In all synergy experiments, total quantity of virus injected was kept constant between groups by co-delivery of Ad.Psi5. In all experiments, tumor volume was monitored using a metric caliper until mice were killed due to excessive tumor size or tumor ulceration. Tumor-free or 'cured' mice were subject to tumor challenge 1-2 months after initial tumor resolution with 1 Â 10 5 MCA205 cells subcutaneously in the abdomen.
In vitro transduction of MCA205 Cells
Immunohistochemistry
Tumors of treated mice were harvested on day 15 post tumor inoculation (day 8 post treatment), snap frozen in 2-methylbutane and stored at À80 1C. Tumors were then cut by cryostat, 10 m sections placed onto charged slides and stained for CD8 and CD31 as follows: for analysis of intratumoral CD8 þ T-cell infiltrate from mice treated with Ad.IL-12 and Ad.IL-23, sections were fixed in À20 1C acetone and slides blocked in Exogenous Peroxidase Block (DAKO, Carpinteria, CA), followed by block in 10% goat serum. CD8 antibody (1:150 dilution; BD Biosciences, San Jose, CA) was then added, followed by incubation with biotinylated goat anti-rat secondary antibody (1:250; BD Biosciences) in DAKO Antibody Diluent (DAKO). Slides were treated with ABC Vectastain kit (Vector Laboratories, Burlingame, CA) and developed using DAB Peroxidase Substrate Kit (Vector Laboratories) following manufacturers' instructions. Slides were then counterstained with eosin, dehydrated in increasing concentrations of ethanol, followed by xylene, and coverslipped using Permount Media (Fisher, Pittsburgh, PA).
Alternatively, for analysis of tumors from mice treated with Ad.IL-12 and Ad.scIL-23, sections were permeabilized using 10% Triton-X (Sigma, St. Louis, MO), blocked in 2% BSA (Sigma) and incubated with rat anti-mouse CD8 antibody (1:100 dilution; BD Biosciences) overnight at room temperature. Slides were then incubated with Alexa-Flour goat anti-rat secondary (1:500 dilution; Invitrogen, Eugene, OR) and coverslipped using Flourmount media (SouthernBiotech, Birmingham, AL).
To investigate tumor angiogenesis, sections were permeabilized with 10% Triton-X (Sigma) followed by block in 2% BSA (Sigma). Sections were then incubated in rat anti-mouse CD31 primary antibody (1:100; BD), followed by Alexa-Flour goat anti-rat secondary (1:500 dilution; Invitrogen).
Statistics
Kaplan-Meier survival curves were plotted using SPSS version 16.0 (SPSS Inc, Chicago, IL). Mice were monitored until excessive tumor volume or tumor ulceration, at which time they were killed and recorded as occurrence of an event (death). Cured mice or those with tumors that did not warrant killing by the end of the experiment were censored. Log-rank tests of the survival curves provided P-values. An unpaired T-test was used to analyze immunohistochemistry results if variances between data were equal; if variances were unequal, the Mann-Whitney U test was performed. Statistical analyses were two-tailed, with a P-value o0.05 considered statistically significant.
Results
Anti-tumor activity of Ad.IL-23 requires endogenous IL-12 Previously, we have shown that adenoviral-mediated, intratumoral delivery of IL-23 resulted in efficient and long-lasting tumor eradication by generating a Th1 immune response dependent upon CD4 þ and CD8 þ T cells and endogenous IFN-g. 23 The cellular and cytokine requirements for the antitumor effects of IL-23 were similar, but not identical, to those of IL-12. Figures 1c and d) . This result demonstrates that Ad.IL-23 antitumor activity is dependent upon endogenous IL-12, not IL-23. However, it is important to note that two tumors from the Ad.IL-12-treated mice recurred at day 35 post tumor inoculation, suggesting lack of induction of strong protective immunity in the absence of endogenous IL-23.
Treatment with Ad.IL-12 and Ad.IL-23 at separate time points does not lead to enhanced antitumor benefit The results in IL-12/23 p40-and IL-23 p19-deficient mice suggest that Ad.IL-23 confers at least part of its antitumor effects by induction of endogenous IL-12. Therefore, we examined whether treatment of tumors with both Ad.IL-12 and Ad.IL-23 would result in an enhanced antitumor effect, resulting in more rapid tumor rejection and subsequent generation of long-lasting protective immunity. We first examined whether treatment with Ad.IL-12 followed by Ad.IL-23 would result in synergistic enhancement of antitumor effects both locally and systemically. C57BL/6 mice bearing tumors on each flank were treated with two injections of Ad.IL-12 and Ad.IL-23 at suboptimal doses (5 Â 10 8 and 2.5 Â 10 10 particles, respectively) into one tumor as follows: Ad.IL-12 on day 7, followed by Ad.IL-23 on day 11 (Ad.IL-12,23); Ad.IL-23 on day 7, followed by Ad.IL-12 on day 11(Ad.IL-23,12); Ad.IL-12 on both days 7 and 11 (Ad.IL-12), Ad.IL-23 on both days 7 and 11 (Ad.IL-23) or Ad.Psi5 on days 7 and 11 (Ad.Psi5). In the injected tumors, treatment with Ad.IL-12 on day 7 followed by Ad.IL-23 on day 11 resulted in a 29% tumor rejection rate that was less than the 43% rejection rate achieved with Ad.IL-12 treatment alone (Figure 2a) . Similarly, Ad.IL-23 treatment on day 7 followed by Ad.IL-12 on day 11 resulted in rejection of only 11% of tumors. A similar trend was observed in the contralateral tumors. Only 14% of the contralateral tumors in mice treated with Ad.IL-12 on day 7 followed by Ad.IL-23 on day 11 were rejected, less than the 42% rejection rate in mice treated with Ad.IL-12 alone (Figure 2b) . Additionally, when mice bearing only one tumor were treated with Ad.IL-12 and Ad.IL-23 as described above, there was no discernable enhancement of the antitumor effects (data not shown). 
Generation and characterization of adenovirus expressing scIL-23
Co-treatment with Ad.IL-12 and Ad.IL-23 did not result in any additive or synergistic antitumor effects over use of either cytokine alone. However, the level of expression of IL-23 from the adenoviral vector used is significantly lower than IL-12 (data not shown). In addition, since IL-12 and IL-23 share the common p40 subunit, it is possible that in vivo coinfection of tumors with Ad.IL-12 and Ad.IL-23 leads to preferential expression of one cytokine over another. Therefore, the lack of therapeutic benefit of co-treatment with Ad.IL-12 and Ad.IL-23 may be a result of suboptimal expression of IL-23 compared with IL-12. Therefore, an adenoviral vector expressing a scIL-23 (Ad.scIL-23) was constructed in which the p40 subunit is linked to the mature p19 subunit using a 15-amino-acid (Gly 4 Ser) 3 spacer (Figure 3a ). (Figures 4a and b) . In both injected and contralateral tumors, 40% of co-treated animals experienced tumor rejection, identical to mice treated with Ad.scIL-23 alone (Figures 4a and b) . Treatment with the suboptimal dose of Ad.IL-12 alone resulted in only a 20% rejection rate in injected tumors and no rejection in the contralateral tumors (Figures 4a  and b) . 
Discussion
IL-12 is a heterodimeric, proinflammatory cytokine comprised of p40 and p35 subunits. IL-23 is a member of the IL-12 family of heterodimeric cytokines and is comprised of p40, which is shared with IL-12, and p19, which is unique to IL-23. IL-12 and IL-23 can act on both innate and adaptive arms of immunity. [1] [2] [3] [4] [5] 14, 15 In addition, adenoviral-mediated, intratumoral delivery of IL-12 or IL-23 results in antitumor effects. 13, 23 In this study we have examined the requirement for endogenous IL-12 and IL-23 for conferring the antitumor effects of gene delivered IL-12 and IL-23. We demonstrated that endogenous IL-12 is required for the antitumor activities of Ad.IL-23, but not for the antitumor effects of Ad.IL-12. In particular, Ad.IL-12 was able to generate an antitumor effect in both p40 and p19 deficient mouse strains. In contrast, Ad.IL-23 was able to confer an antitumor therapeutic effect in p19 deficient, but not in p40 deficient mice. However, it is important to note that in the p19-deficient mouse background, some of the Ad.IL-12 treated, the tumor-free animals experienced tumor recurrence at later time points. Thus it is possible that IL-23 has a role in establishing IL-12-mediated, systemic antitumor immunity. These results also are consistent with previous results demonstrating that the antitumor effects of systemic IL-23 required endogenous p35. 22 Given the fact that Ad.IL-23 requires IL-12 for its antitumor effects and that IL-23 could contribute to the induction of antitumor immunity by IL-12, it is possible that the two cytokines may synergize to eradicate tumors. However, no enhancement in systemic antitumor immunity was observed in mice bearing two tumors One concern regarding the use of an adenoviral vector expressing both subunits from a single transcript via an internal ribosome entry site is that the level of IL-12 expression was consistently higher than that of IL-23, suggesting variable levels of expression between the two subunits. Thus, the amount of virus needed to confer an antitumor effect with IL-23 was an order of magnitude higher than with Ad.IL-12. Also, even at higher doses of Ad.IL-23, the magnitude of the antitumor effect was less than that of Ad.IL-12. To increase the expression of IL-23, we generated an adenoviral vector expressing a scIL-23 that expressed almost 1000-fold greater amounts of biologically active IL-23 than its double-chain counterpart. Intra-tumoral injection of Ad.scIL-23 had more potent antitumor activity, with treatment resulting in significant enhancement of survival, complete tumor rejection in 90% of animals and establishment of strong protective immunity. In fact, the efficiency of inducing an antitumor effect with scIL-23 approached that observed with IL-12. In addition, in spite of high expression levels, Ad.scIL-23 treatment showed no evidence of the toxicity that is observed when using high doses of Ad.IL-12. The fact that potent systemic antitumor immunity was observed following intratumoral delivery of Ad.scIL-23 supports the further development of a scIL-23 vector for therapeutic treatment of cancer.
Despite the higher levels of IL-23 expression obtained with Ad.scIL-23, no synergistic antitumor effect was observed when Ad.IL-12 and Ad.IL-23 were co-delivered. Co-treatment resulted in tumor eradication rates that were identical treatment with Ad.scIL-23 alone in both injected and contralateral tumors. To examine possible mechanisms for the lack of synergy, histology was performed on the treated tumors. Co-treatment with Ad.IL-12 and Ad.scIL-23 did not alter CD4 or Foxp3-positive or DC infiltrate compared with use of either virus alone or control treatment. Co-treatment did, however, significantly enhance CD8 þ T-cell infiltrate compared with use of Ad.scIL-23 alone. Angiogenesis also was not altered in tumors treated with both Ad.IL-12 and Ad.scIL-23, or either virus alone, compared with controls.
Our observation that there is no evidence of synergy between IL-12 and IL-23 is supported by a previous study. C57BL/6 mice bearing scIL-23-secreting B16 tumors did not show enhanced tumor rejection when co-treated with recombinant IL-12 intraperitoneally. 27 Taken together, the results strongly suggest that these two cytokines simply do not synergize due to their contrasting and mutually exclusive functions: IL-12 strongly drives IFN-g expression and a Th1 response, while IL-23 is capable of driving IL-17 expression and a Th17 response. Although in our model it did not appear that IL-23-mediated eradication of tumors was mediated by a Th17 response (data not shown), it is possible that Th17 T cells were generated. Furthermore, it has been shown that Th17 cells inhibit CD8 þ T-cell cytotoxicity. 29, 30 Therefore, co-expression of IL-23 with IL-12 may skew the resulting immune response away from a Th1 phenotype and result in lack of enhancement of antitumor effects.
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